Related Experiment Video

Updated: May 1, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.3K

Renal cell carcinoma: molecular biology and targeted therapy

Daniel Su1, Lambros Stamatakis, Eric A Singer

  • 1aUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland bSection of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.

Current Opinion in Oncology
|March 29, 2014
PubMed
Abstract

Insights

New targeted therapies and immunotherapies show promise for metastatic renal cell carcinoma (mRCC). Continued research is vital to optimize treatments and improve durable responses in patients with kidney cancer.

Area of Science:

  • Oncology
  • Translational Research

Background:

  • Renal cell carcinoma (RCC) is under extensive clinical and translational investigation.
  • Systemic therapies are evolving, with new molecular pathways and immunotherapy approaches emerging.

Purpose of the Study:

  • To discuss advances in systemic targeted therapies for renal cell carcinoma.
  • To review new molecular pathways and immunotherapy approaches for treating metastatic RCC.

Main Methods:

  • Review of current clinical and translational research.
  • Analysis of systemic targeted therapies and immunomodulatory agents.

Main Results:

  • Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathway inhibitors remain standard for metastatic RCC (mRCC).
  • While newer agents have improved toxicity, durable complete responses are infrequent.
  • Emerging data suggest potential for immunomodulatory agents in mRCC treatment.

Conclusions:

  • The therapeutic options for genitourinary oncologists treating mRCC are expanding.
  • Further research is needed to fully leverage targeted strategies and immunotherapy for improved patient outcomes.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

9.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.6K